科前生物(688526) - 2025 Q4 - 年度业绩

Financial Performance - In 2025, the company achieved total operating revenue of RMB 950.29 million, an increase of 0.89% compared to the previous year[4] - The net profit attributable to shareholders of the listed company reached RMB 415.60 million, reflecting an increase of 8.70% year-on-year[4] - Basic earnings per share increased to RMB 0.90, representing a growth of 9.76% from the previous year[4] - The company reported a net profit after deducting non-recurring gains and losses of RMB 350.28 million, an increase of 12.31% year-on-year[4] - The weighted average return on net assets was 10.16%, an increase of 0.27 percentage points compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 4.79 billion, a growth of 6.55% from the beginning of the year[5] - Shareholders' equity attributable to the listed company was RMB 4.24 billion, up 7.64% compared to the start of the year[5] Research and Development - The company has intensified its R&D efforts and accelerated new product development to enhance market competitiveness[6] Financial Data Integrity - There were no financial data items with a change of 30% or more during the reporting period[6] - The company emphasizes the importance of investor awareness regarding potential risks due to preliminary financial data not yet audited[8]